What does the Zepbound label say after a missed dose?
The current U.S. prescribing information gives one missed-dose instruction for all labeled strengths: take the missed dose as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip it and take the next dose on the regular day. Allow at least 72 hours between doses if changing the weekly day. The label does not specify a separate restart protocol for 2.5 mg, 5 mg, or higher dose tiers.
What the label does not establish
The label does not say that one missed week causes a predictable appetite rebound on days 10 to 14, a particular percentage drop in blood concentration, or lost titration progress. Those are not labeled missed-dose outcomes. The previous dose-tier decision tree and numerical blood-level claims are removed.
| Time since scheduled dose | Label instruction |
|---|---|
| Within 4 days (96 hours) | Administer the missed dose as soon as possible. |
| More than 4 days | Skip it and take the next dose on the regularly scheduled day. |
| Changing the weekly day | Allow at least 72 hours between doses. |
Primary source
Current DailyMed U.S. prescribing information for Zepbound, section 2.3.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. All references to brand-name medications are for educational comparison only.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →